Physician profile
John M Tieman
NPI 1114089844
$2,021.64
in general payments reported to CMS, 2019-2025
13 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.83 · 2023: $134 · 2024: $938 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.83 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $270.02 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $251.46 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $246.26 | 2019-2025 | |
| Galderma Laboratories, L.P. | $211.54 | 2024-2025 | Nemluvio |
| Ucb, INC. | $166.70 | 2024-2025 | Bimzelx |
| Abbvie INC. | $166.30 | 2023-2025 | Skyrizi, Botox |
| Genzyme Corporation | $159.44 | 2023-2025 | |
| Medtronic, INC. | $130.58 | 2024 | Kyphon Express II Kyphopak Tray |
| Regeneron Healthcare Solutions, INC. | $124.37 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $123.45 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $107.95 | 2023-2025 | Opzelura |
| Organon LLC | $44.93 | 2025 | Vtama |
| Botanix Sb INC | $18.64 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tieman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.